Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deciphera Pharmaceuticals
Biotech
Deciphera's tumor-tackling oral med achieves 40% response rate
Deciphera's success with vimseltinib comes as Qinlock's revenue rose nearly 30% in the third quarter compared to the same period in 2022.
Max Bayer
Oct 30, 2023 11:00am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Deciphera nabs speedy review for GIST cancer hopeful
Feb 13, 2020 7:32am
Deciphera files for approval of cancer drug ahead of schedule
Dec 16, 2019 8:20am
Deciphera soars as phase 3 cancer data tee up FDA filing
Aug 13, 2019 8:39am
FDA chief Scott Gottlieb steps down—Chutes & Ladders
Mar 8, 2019 9:00am
